Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

776.25 +39.05 (+5.30%)
Streaming Delayed Price Updated: 11:07 AM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
75 76 Next >
Why Dexcom — And The Obesity Market — Could Benefit From This New FDA Win
The FDA granted Dexcom's Stelo a broad clearance, meaning people without diabetes can use it. 
Via Investor's Business Daily
Exposures Product Safety
Escalating Demand for Obesity Drugs Creates Time-Sensitive Race for Eli Lilly, Novo Nordisk
Eli Lilly's strategic collaborations with outsourcing partners for Zepbound (tirzepatide) production. Challenges persist as Eli Lilly and Novo Nordisk address production bottlenecks amid rising... 
Via Benzinga
Is Viking Therapeutics Stock a Better Buy Than Eli Lilly and Novo Nordisk After the Latest Weight-Loss Drug News?
A new player in the multibillion-dollar weight-loss drug market could be waiting in the wings. 
Via The Motley Fool
Why Dialysis Stocks DaVita, Fresenius Soared On Novo's Ozempic News
Novo Nordisk tested its diabetes and weight-loss drug in patients with chronic kidney disease. 
Via Investor's Business Daily
Prediction: Eli Lilly and Novo Nordisk Stock Could Just be Getting Started. Here's Why
Eli Lilly and Novo Nordisk dominate the diabetes market thanks to blockbuster medications Mounjaro, Ozempic, and Rybelsus. 
Via The Motley Fool
Eli Lilly and Co Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Is It Too Late to Buy Eli Lilly Stock Now?
Eli Lilly stock is having a moment, but the company could easily continue soaring. 
Via The Motley Fool
A Closer Look at 18 Analyst Recommendations For Eli Lilly and Co
Via Benzinga
Better Weight Loss Drug Stock: Viking Therapeutics vs. Eli Lilly
One is a reigning champion, and the other is a burgeoning contender. 
Via The Motley Fool
Jim Cramer Says Nvidia, Eli Lilly, Novo Nordisk Are Not Overvalued: 'Will Be Ready To Buy If This Market Sells Off'
Cramer suggested that the upcoming labor report could potentially trigger a buying opportunity, predicting stronger figures than expected by Wall Street. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
It’s Time! 3 Dodgy Pharma Stocks to Sell in February
Explore pharma stocks to sell in February: Eli Lilly, Amgen, BioNTech face overvaluation, volatility, urging investor action. 
Via InvestorPlace
1 Wall Street Analyst Thinks Eli Lilly Stock Is Going to $1000. Is It a Buy Around $782?
There are two big reasons why Eli Lilly stock is as much as 5x more expensive than Pfizer. 
Via The Motley Fool
$1000 Invested In This Stock 10 Years Ago Would Be Worth $13,000 Today
Via Benzinga
Here's How Much You'd Have If You Invested $10,000 in Eli Lilly Stock When Billionaire George Soros First Bought It
The tricky part would have been to not sell the pharmaceutical giant's shares when Soros did. 
Via The Motley Fool
This Is the Biggest Company Not in the "Magnificent Seven" -- but It Deserves to Be
It's in a distinctly different business than the "Magnificent Seven" companies, but it deserves the same attention. 
Via The Motley Fool
Better Blockbuster-Drug Stock: Novo Nordisk vs. Eli Lilly
This is a close contest, and it'll go on for at least a few more rounds. 
Via The Motley Fool
Better Buy: Eli Lilly vs. Viking Therapeutics
These two biotechs could eventually go head to head in a fast-growing market. 
Via The Motley Fool
3 Magnificent Growth Stocks to Buy in March
These three stocks have two important common denominators: the same industry and tremendous growth prospects. 
Via The Motley Fool
Why Novo Nordisk Stock Topped the Market Today
A favorite of both investors and analysts gets a boost from a bullish move by a pundit. 
Via The Motley Fool
Record-High S&P 500 Propels SPY ETF To $500-Billion Milestone, Nvidia Tops $2 Trillion, Broadcom Surpasses Tesla
U.S. stock market continues bull run, hitting record highs for S&P 500 and Nasdaq 100. SPY ETF surpasses $500 billion AUM, with other companies also reaching milestones. 
Via Benzinga
Topics ETFs Stocks
Exposures US Equities
Eli Lilly's Commercial Moat, Competitor Landscape: BofA Emphasizes Strength in Incretin Space, Undervalued Assets
Eli Lilly: BofA Securities rates it a top pick in Biopharma, with a YTD performance of +29%. Analysts highlight undervalued opportunities in heart disease, sleep apnea, and liver disease. Price target... 
Via Benzinga
Stock Market Rally At Highs After Big Earnings, Inflation Data: Weekly Review
The Nasdaq is on the cusp of setting a record high. 
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
Eli Lilly Stock And The Road To 1,000: Weight-Loss Drugs Could Generate $81 Billion
Wall Street isn't properly taking into account Lilly's next-generation drugs, an analyst says. 
Via Investor's Business Daily
3 Healthcare Stocks That Have Outperformed Nvidia Since 2022
The healthcare sector is no slouch when it comes to top-performing growth stocks. 
Via The Motley Fool
Got $200? 2 Dividend Stocks to Buy and Hold Forever
Trust these two real estate stocks to be attractively priced and proven performers. 
Via The Motley Fool
2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years
It will take a lot, but this goal isn't out of reach for these stocks. 
Via The Motley Fool
The Hot List: 3 AI Stocks Worth Buying on Weakness
Firms using AI directly can be great picks for long-term investors, such as these three AI stocks to buy on weakness. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
These 4 Stocks Are the "Magnificent Seven" of Healthcare
Their growth trajectories aren't as meteoric, but they're still notable. 
Via The Motley Fool
Ozempic, Wegovy Other Weight-Loss Drugs Won't Solve Global Obesity Crisis Affecting 1B People, WHO Warns
The World Health Organization has cautioned that the increasing global obesity crisis, which now affects over a billion people, cannot be resolved by the use of obesity medications alone. 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
75 76 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.